Small molecule compound ZYZ-384 targets SMYD3 to alleviate aging

Area of Science:

• Biochemistry
• Cell Biology
• Gerontology

Background:

• SMYD3 is a key chromatin modifier regulating histone 3 lysine 4 trimethylation (H3K4me3) and diverse biological activities.
• Cellular senescence is a complex aging process implicated in various age-related diseases.
• Targeting SMYD3 presents a potential therapeutic strategy for combating aging.

Purpose of the Study:

• To evaluate the anti-senescence and anti-aging effects of ZYZ-384, a novel SMYD3 inhibitor.
• To investigate the impact of ZYZ-384 on cellular proliferation and aging markers in vitro and in vivo.
• To elucidate the molecular mechanisms underlying ZYZ-384's anti-aging properties.

Main Methods:

• Induction of senescence in human (HMEC-1) and mouse (SVEC4-10) endothelial cells using angiotensin II.
• Establishment of D-galactose-induced subacute and natural senescence animal models.
• Assessment of cellular proliferation, aging markers, senescence-associated secretory phenotype (SASP), differential metabolites, SMYD3, H3K4me3, HSP 90, and NF-κB.

Main Results:

• ZYZ-384 significantly inhibited aging markers and promoted cell proliferation in both senescent cell and animal models.
• The compound suppressed the expression of SMYD3 and H3K4me3.
• ZYZ-384 also reduced the overexpression of HSP 90 and NF-κB in senescent models.

Conclusions:

• ZYZ-384 demonstrates potent anti-senescence and anti-aging effects.
• Targeting SMYD3 with ZYZ-384 offers a promising therapeutic approach for age-related conditions.
• The study validates ZYZ-384 as an effective SMYD3 inhibitor for delaying aging.